Some children and adults who are suffering with asthma because of an inability to take certain medications will be excited to hear the news of a new asthma treatment that is being researched by scientists.
The drug was developed by scientists from the Rutgers New Jersey Medical School and the Shanghai University, and has been shown to offer advanced relief from asthma. Known as metallothionein-2 (MT-2), the protein occurs naturally in the body and is shown to be available in decreased amounts amongst those who have asthma. It was discovered that an MT-2-based drug known as 'TSG12' was able to provide increased breathing abilities amongst mice with efficacy being more effective than inhalers. The new asthma treatment has been proved to be non-toxic for human cells, which is supporting the next step in the development process that focuses on clinical trials.
Image Credit: Depositphotos
Key Themes Behind This Trend
- Advanced Asthma Treatments
- The development of metallothionein-2 (MT-2) as a potential asthma treatment presents an opportunity for advanced asthma therapies without side effects.
- Protein-based Drugs
- The use of protein-based drugs like 'TSG12' derived from metallothionein-2 (MT-2) could revolutionize asthma treatment by offering a new class of medications.
- Non-toxic Medications
- The creation of non-toxic asthma drugs such as 'TSG12' paves the way for a safer and more effective alternative to traditional inhalers.
Where This Applies
- Pharmaceuticals
- The pharmaceutical industry can explore the development of advanced metallothionein-2 (MT-2) based drugs for asthma treatment.
- Biotechnology
- Biotech companies can leverage protein-based medications derived from metallothionein-2 (MT-2) to address unmet needs in respiratory health.
- Medical Research
- The medical research field can conduct clinical trials to further investigate the efficacy and safety of metallothionein-2 (MT-2) as a potential asthma treatment.
